- Pfizer reached an agreement with the U.S. government to offer major prescription drugs at steep discounts through a new federal online platform.
- The deal led to a more than 2% rise in Pfizer’s Indian-listed shares on Wednesday.
- Under the agreement, some medications will be discounted by 50% to 100% for direct cash payment via the TrumpRX website.
- All newly launched Pfizer drugs in the U.S. will be priced at rates matching the lowest charged internationally.
- Companies that do not reduce prices could face additional tariffs of 5% to 8% as the administration encourages local production.
Pfizer has entered into a deal with the U.S. government to sell essential prescription drugs at significant discounts through a new federal website called TrumpRX. This announcement was made by President Donald Trump at the White House, resulting in a boost of over 2% for Pfizer’s Indian-listed shares on Wednesday.
According to the agreement, Pfizer will offer several key medicines at discounts ranging from 50% to 100%. Patients can pay cash directly on the TrumpRX online platform. The company also pledged that all new drugs introduced in the U.S. will be sold at the “most favored patient costs,” ensuring prices are comparable to the lowest rates offered internationally.
Pfizer CEO Albert Bourla confirmed that the arrangement meets all the government’s requirements. “The President is absolutely right—tariffs are the most powerful tool to motivate behavior, and they clearly motivated ours,” Bourla said. Under the deal, Pfizer has secured a three-year grace period from proposed tariffs on pharmaceutical imports while reducing prices on select drugs.
President Trump stated that companies failing to decrease prices could face extra tariffs between 5% and 8%. The administration is encouraging drugmakers to expand U.S.-based manufacturing ahead of a deadline on October 1, 2025.
Market expert Sunil Kotak noted Pfizer’s share price has shown a sideways trend, with its 50-day simple moving average around $62, and a strong supply zone between $62 and $63. He indicated a close above $63 would be needed for further upward movement. The stock’s relative strength index stands at 52, suggesting current consolidation.
Until now in 2025, Pfizer’s stock is reported to have declined by 2.8%.
Previous Articles:
- Sei Expands in Asia With Japan License, Eyes Institutional Growth
- Federal Government Shuts Down as Senate Deadlocks on Funding
- Apple Rejects Musk’s Claim of Favoritism in OpenAI Partnership
- Coinbase’s D’Agostino: AI Agents Need Crypto for Fast Finance
- Pfizer Soars 6.8% as TrumpRx.gov Direct Drug Deal Slashes Prices
